Investigational Treatment

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, King Edward Medical University

Conditions

Actinic KeratosisCOVID-19External Genital Warts

Phase 2

Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients

CompletedNCT02404389

Novartis PharmaceuticalsActinic Keratosis

Start: 2015-03-05End: 2016-01-27Updated: 2021-01-05

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

CompletedNCT02482428

Novartis PharmaceuticalsExternal Genital Warts

Start: 2015-05-12End: 2016-05-31Updated: 2021-01-05

Unknown Phase

Nutritional Supplementation of Flavonoids Quercetin and Curcumin for Early Mild Symptoms of COVID-19

CompletedNCT05130671

King Edward Medical UniversityCOVID-19

Start: 2021-10-25End: 2021-12-31Updated: 2022-01-28

Related Papers

Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19—Results From a Pilot Open-Label, Randomized Controlled Trial

Frontiers in Pharmacology2022-06-0752 citations